SAN DIEGO--(BUSINESS WIRE)--Selva Therapeutics, Inc. (“Selva”) announced new preclinical data demonstrating SLV213, when given as a prophylactic or a treatment for SARS-CoV-2 infection, protects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback